Working… Menu
Trial record 1 of 1 for:    NCT03117920
Previous Study | Return to List | Next Study

A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer (MinPAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03117920
Recruitment Status : Unknown
Verified September 2017 by Queen Mary University of London.
Recruitment status was:  Recruiting
First Posted : April 18, 2017
Last Update Posted : September 14, 2017
Minneamrita Therapeutics LLC
Barts & The London NHS Trust
Translational Genomics Research Institute
Information provided by (Responsible Party):
Queen Mary University of London

Brief Summary:

MinPAC aims to see if the drug Minnelide can slow down tumour growth in patients with pancreatic cancer that is not responding to treatment. Minnelide is designed to rapidly release the anti-tumour molecule triptolide in the bloodstream and has been shown to slow cancer cell growth and induce cancer cell death. Minnelide is currently being investigated in other early phase trials and has shown promising response data.

There are strict eligibility criteria for this trial. Broadly speaking, patients with pancreatic cancer that has spread to other organs and has progressed on one or more chemotherapy regimens are eligible. Participants will receive Minnelide on days 1-21 of each 28 day cycle until their cancer stops responding to treatment. After that participants will be followed up 3 monthly for the collection of disease status and survival data.

MinPAC includes biological and imaging studies. Participants will be asked to donate tumour and blood samples and will be asked to undergo additional PET Scans. The study is being carried out in 4 sites in the UK and USA.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: Minnelide Phase 2

Detailed Description:
MinPAC is an open label, international, multicentre phase II trial that aims to evaluate the effects of Minnelide treatment in patients with refractory pancreatic cancer. Eligible patients will receive Minnelide until disease progression unless there is evidence of unacceptable toxicity or the patient requests to be withdrawn from the study treatment. Once disease progression is documented, patients will enter a follow up phase during which data will be collected on further disease and survival status. If patients are unable to attend hospital visits during the follow up period then data will be collected either via telephone or via national registries with the patient's consent. The efficacy of Minnelide will be assessed on CT/MRI scan images and tumour and/or blood samples collected at baseline, during treatment and on completion of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm, open label study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: MinPAC: A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer.
Actual Study Start Date : April 10, 2017
Estimated Primary Completion Date : May 15, 2018
Estimated Study Completion Date : February 15, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Minnelide
0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
Drug: Minnelide
Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).

Primary Outcome Measures :
  1. Disease Control rate (DCR) [ Time Frame: Enrolment to 16 weeks ]
    DCR (CR+PR+SD) by RECIST v1.1

Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: Disease progression or death, assessed up to 18 months ]
    Time from enrolment until disease progression or death from any cause, whichever occurs first (RECIST v1.1)

  2. Incidence of adverse events [ Time Frame: Through completion of the safety visit an average of 4 months ]
    Adverse events by CTCAE v4.03

  3. Overall survival (OS) [ Time Frame: Death, assessed up to 18 months ]
    Time from enrolment until death

  4. Response rate (RR) [ Time Frame: Enrlolment to 16 weeks ]
    Percentage of individuals on study attaining a CR + PR (RECIST v1.1)

  5. Change in tumour size and volume [ Time Frame: Baseline to 8 weeks ]
    Change in the sum of diameters of the target lesions

  6. Change in CA19-9 levels [ Time Frame: Through completion of the treatment period an average of 4 months ]
    Percentage of patients with >20% decrease

  7. Pharmacodynamic effect of Minnelide on tumour using PET Scans [ Time Frame: 8 weeks ]
    Changes in SUV

Other Outcome Measures:
  1. Biomarkers predictive of response to Minnelide [ Time Frame: Through completion of the treatment period an average of 4 months ]
    Changes in circulating tumour stem cells.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Willing and able to provide written informed consent.
  2. Ability to comply with the protocol.
  3. Aged ≥ 18 years.
  4. Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma that has progressed on one or more chemotherapy regimens.
  5. Karnofsky performance status ≥ 70%.
  6. At least one lesion that can be measured accurately at baseline as ≥10mm in the longest diameter (except lymph nodes which must have a short axis ≥15mm) with CT/MRI and which is suitable for repeated measurements per RECIST v1.1
  7. Adequate haematological and end-organ function, as per the local institutions reference ranges, within 72 hrs prior to day 1 of cycle 1 of treatment defined by the following:
  8. Life expectancy ≥ 12 weeks.
  9. Negative pregnancy test within 14 days of day 1 cycle 1 for female patients of childbearing potential.
  10. Tumour sites amenable to repeated biopsies.
  11. Willingness to undergo paired tumour biopsies during the trial.
  12. Agreement to use adequate contraception from 2 weeks before the start of treatment with Minnelide and until 90 days after completion of treatment.

Exclusion Criteria:

  1. Patients with known or suspected brain metastasis
  2. Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction within 6 months prior to enrolment, unstable arrhythmia, or evidence of ischemia on ECG.
  3. Baseline QTc exceeding 450msec (470msec for females) and / or patients receiving class 1A or class III anti-arrhythmic agents.
  4. Known HIV, Hepatitis A, B or C infection.
  5. Malignancies other than pancreatic cancer ≤5 years prior to Minnelide cycle 1 day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcomes (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer or ductal carcinoma in situ treated surgically with curative intent) or localised prostate cancer treated with curative intent and absence of PSA relapse or incidental prostate cancer (Gleason score ≤3 +4 and PSA <10ng/L undergoing active surveillance and treatment naïve).
  6. Severe infections ≤ 4 weeks prior to enrolment in the study as well as active, uncontrolled bacterial, viral or fungal infections requiring systemic treatment.
  7. Major surgical procedure ≤ 2 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
  8. Treatment with chemotherapy or other investigational agents within 28 days (or at least 5 x the half-life of the drug) prior to day 1 cycle 1 of Minnelide™ (6 weeks for nitrosoureas or Mitomycin C).
  9. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational medicinal product (IMP) within ≤ 5 x the half-life of the IMP prior to day 1 cycle 1 of Minnelide.
  10. Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of Minnelide, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
  11. Female patients who are pregnant or nursing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03117920

Layout table for location contacts
Contact: MinPAC Trial Coordinator 00442078828197
Contact: Kelly Mousa 00442078828197

Layout table for location information
United States, Arizona
HonorHealth Research Institute Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Joyce Schaffer    480-323-1339   
Principal Investigator: Erkut Borazanci         
United States, California
Moores UC San Diego Cancer Center Recruiting
La Jolla, California, United States, 92037
Contact: Michelle Mendoza    858-822-6937   
Principal Investigator: Hitendra Patel, MD         
United States, Pennsylvania
University of Pennsylvania Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Peter O'Dwyer    215-360-0716      
Principal Investigator: Peter O'Dwyer         
United Kingdom
Barts Health NHS Trust Not yet recruiting
London, United Kingdom, E1 1BB
Contact: David Propper         
Principal Investigator: David Propper         
Sponsors and Collaborators
Queen Mary University of London
Minneamrita Therapeutics LLC
Barts & The London NHS Trust
Translational Genomics Research Institute
Layout table for investigator information
Principal Investigator: David Propper Barts & The London NHS Trust
Principal Investigator: Erkut Borazanci HonorHealth Research Institute

Layout table for additonal information
Responsible Party: Queen Mary University of London Identifier: NCT03117920     History of Changes
Other Study ID Numbers: Minnelide002
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: September 14, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Queen Mary University of London:
Refractory pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases